Sequenom, Inc.  

(Public, NASDAQ:SQNM)   Watch this stock  
Find more results for Michael Gunter
-0.02 (-0.79%)
Apr 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.40 - 2.53
52 week 1.65 - 4.90
Open 2.51
Vol / Avg. 1.56M/1.60M
Mkt cap 290.74M
P/E     -
Div/yield     -
EPS -0.93
Shares 116.30M
Beta 0.25
Inst. own 50%
Jun 10, 2014
Sequenom 2014 Annual Shareholder Meeting Add to calendar
May 5, 2014
Q1 2014 Sequenom Earnings Release (Estimated) Add to calendar
Mar 11, 2014
Sequenom at ROTH Conference
Feb 27, 2014
Q4 2013 Sequenom Earnings Conference Call
Feb 27, 2014
Q4 2013 Sequenom Earnings Release
Jan 16, 2014
Sequenom at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -41.83% -66.13%
Operating margin -36.90% -60.59%
EBITD margin - -47.56%
Return on average assets -48.92% -54.57%
Return on average equity - -14282.71%
Employees 570 -
CDP Score - -


3595 John Hopkins Court
SAN DIEGO, CA 92121-1331
United States - Map
+1-858-2029000 (Phone)
+1-858-2029001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Sequenom, Inc. (Sequenom) is a molecular diagnostic testing and genetics analysis company committed to providing molecular diagnostic testing services, and research use only products, services, applications, and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural, livestock, and other areas of research. The Company�s development and commercialization efforts in various diagnostic areas include noninvasive women�s health-related and prenatal diagnostics, ophthalmology, and other medical conditions, such as oncology, infectious diseases and autoimmunity. The Company operates in two segments: Molecular Diagnostics (including Sequenom Center for Molecular Medicine, LLC, or Sequenom CMM) and Genetic Analysis. In November 2011, the Company entered into leases for additional laboratory and office space in San Diego, California and Durham, North Carolina.

Officers and directors

Harry F. Hixson Jr., Ph.D. Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
Paul V. Maier Chief Financial Officer
Age: 65
Bio & Compensation  - Reuters
William J. Welch President, Chief Executive Officer, Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
R. William Bowen Senior Vice President, General Counsel, Secretary
Age: 60
Bio & Compensation  - Reuters
Michael Monko Senior Vice President - Genetic Analysis
Age: 53
Bio & Compensation  - Reuters
Robin G. Weiner Senior Vice President - Quality and Regulatory Affairs
Age: 57
Bio & Compensation  - Reuters
Dirk van den Boom Ph.D. Chief Scientific & Strategy Officer
Age: 43
Bio & Compensation  - Reuters
Carolyn D. Beaver Chief Financial Officer, Chief Accounting Officer, Vice President
Age: 56
Bio & Compensation  - Reuters
Charles R. Cantor Ph.D. Chief Scientific Officer
Age: 70
Bio & Compensation  - Reuters
Alisa Judge Vice President - Human Resources
Age: 57
Bio & Compensation  - Reuters